Tweet
Eur J Cancer
. 2021 Apr 1;150:232-239.
doi: 10.1016/j.ejca.2021.03.030. Online ahead of print.
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)
David Tougeron 1 , Maxime Hentzien 2 , Barbara Seitz-Polski 3 , Firouze Bani-Sadr 2 , Jean Bourhis 4 , Michel Ducreux 5 , S?bastien Gaujoux 6 , Philippe Gorphe 7 , Boris Guiu 8 , Kh? Hoang-Xuan 9 , Florence Huguet 10 , Thierry Lecomte 11 , Astrid Li?vre 12 , Christophe Louvet 13 , L?on Maggiori 14 , Laura Mansi 15 , Pascale Mariani 16 , Pierre Michel 17 , Am?lie Servettaz 2 , Juliette Thariat 18 , Virgine Westeel 19 , Thomas Aparicio 20 , Jean-Yves Blay 21 , Olivier Bouch? 22 , for Th?saurus National de Canc?rologie Digestive (TNCD); r?seau de Groupes Coop?rateurs en Oncologie (GCO); F?d?ration Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Association de Chirurgie H?pato-Bilio-Pancr?atique et Transplantation (ACHBT); Association de Recherche sur les Cancers Gyn?cologiques-Groupes d'Investigateurs Nationaux pour l'?tude des Cancers Ovariens et du Sein (ARCAGY-GINECO); F?d?ration Francophone de Canc?rologie Digestive (FFCD); Groupe Coop?rateur multidisciplinaire en Oncologie (GERCOR); Groupe d'Oncologie Radioth?rapie T?te et Cou-Intergroupe ORL (GORTEC-Intergroupe ORL); Intergroupe Francophone de Canc?rologie Thoracique (IFCT); InterGroupe Coop?rateur de Neuro-Oncologie/Association des Neuro-Oncologues d?Expression Fran?aise (IGCNO-ANOCEF); Soci?t? Fran?aise de Chirurgie Digestive (SFCD); Soci?t? Fran?aise d?Endoscopie Digestive (SFED); Soci?t? Fran?aise de Radioth?rapie Oncologique (SFRO); Soci?t? Fran?aise de Radiologie (SFR); Soci?t? Nationale Fran?aise de Colo-Proctologie (SNFCP); Soci?t? Nationale Fran?aise de Gastroent?rologie (SNFGE)
Affiliations
- PMID: 33934060
- DOI: 10.1016/j.ejca.2021.03.030
Abstract
The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in patients with cancer and also to restore normal cancer care. Patients with cancer to be targeted for vaccination are difficult to define owing to the limited contribution of these patients in the phase III trials testing the different vaccines. It seems appropriate to vaccinate not only patients with cancer with ongoing treatment or with a treatment having been completed less than 3 years ago but also household and close contacts. High-risk patients with cancer who are candidates for priority access to vaccination are those treated by chemotherapy. The very high-priority population includes patients with curative treatment and palliative first- or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large volume of lung, lymph node and/or haematopoietic tissue. When possible, vaccination should be carried out before cancer treatment begins. SARS-CoV-2 vaccination can be performed during chemotherapy while avoiding periods of neutropenia and lymphopenia. For organisational reasons, vaccination should be performed in cancer care centres with messenger RNA vaccines (or non-replicating adenoviral vaccines in non-immunocompromised patients). Considering the current state of knowledge, the benefit-risk ratio strongly favours SARS-CoV-2 vaccination of all patients with cancer. To obtain more data concerning the safety and effectiveness of vaccines, it is necessary to implement cohorts of vaccinated patients with cancer.
Keywords: COVID-19; Chemotherapy; Coronavirus; Radiotherapy; SARS-CoV-2; Solid cancers; Vaccination.